CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 13, 2021
Result type: Reports
Project Number: SR0667-000
Product Line: Reimbursement Review

Generic Name: dupilumab

Brand Name: Dupixent

Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.

Therapeutic Area: Asthma

Indications: Dupixent is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.

Manufacturer Requested Reimbursement Criteria1: Add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid dependent asthma with the following characteristics: 2 or more clinically significant asthma exacerbations in the last 12 months AND Blood eosinophils 150/mcL; OR FeNO 25 ppb; OR Treatment with maintenance oral corticosteroids; OR Clinically allergen-driven asthma

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open October 29, 2020
Call for patient/clinician input closed December 17, 2020

- Patient input submission received from the Lung Health Foundation / Ontario Lung Association

Submission received November 26, 2020
Submission accepted December 10, 2020
Review initiated December 11, 2020
Draft CADTH review report(s) provided to sponsor for comment March 04, 2021
Deadline for sponsors comments March 15, 2021
CADTH responses on draft review report(s) provided to sponsor April 09, 2021
Expert committee meeting (initial) April 21, 2021
Draft recommendation issued to sponsor May 05, 2021
Draft recommendation posted for stakeholder feedback May 13, 2021
End of feedback period May 28, 2021
Final recommendation issued to sponsor and drug plans June 08, 2021
Final recommendation posted June 24, 2021
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) June 22, 2021
CADTH review report(s) posted -